Ertapenem for multiple β-lactamases producing Gram-negative bacteria causing urinary tract infections in HIV patients

| 2017 | 1 Centre for AIDS Research and Education (YRG CARE), South India. The Gram‐negative bacterial isolates were screened for ESBLs production using cefotaxime (30 μg) and ceftazidime (30 μg) alone and in combination with clavulanic acid (10 μg), for MBL production using imipenem (10 μg) alone and in combination with ethylenediaminetetraacetic acid (EDTA) (750 μg), and for AmpC production using cefoxitin (30 μg) alone and in combination with cloxacillin (200 μg) by combination disc method. Of the 128 urinary isolates, 73 (50.7%) were E. coli, 19 (13.2%) Klebsiella pneumoniae, 17 (11.8%) Klebsiella oxytoca, 9 (6.3%) Proteus mirabilis, 2 (1.4%) Proteus vulgaris, and 8 (5.5%) Pseudomonas aeruginosa. Out of 128 bacterial isolates, 120 belonged to Enterobacteriaceae family and 8 to Pseudomonas aeruginosa. Among the bacterial isolates of Enterobacteriaceae, 63 (52.5%) showed positive for ESBLs, 62 (51.66%) for MBLs, and 60 (50%) for AmpC, and among the bacterial isolates of 8 Pseudomonas aeruginosa, 4 (50%) showed positive for ESBLs and 5 (62.5%) for both MBLs and AmpC. It was also observed that ESBLs producing isolates showed minimum inhibitory concentration (MIC) values ranging Sir, Extended‐spectrum β‐lactamases (ESBLs) and AmpC β‐lactamases (AmpC) are responsible for β‐lactam antibiotic resistance among Escherichia coli.[1] Metallo‐β‐lactamases (MBLs) hydrolyze virtually all drugs in the class of carbapenems. This study was aimed to detect the ESBLs, MBLs, and AmpC production among Gram‐negative bacteria from HIV patients. A total of 128 bacterial isolates were collected from urine samples of HIV patients having the symptoms of urinary tract infections (UTIs), attending Y. R. Gaitonde L e t t e r t o e d it o r Ertapenem for multiple β‐lactamases producing Gram‐negative bacteria causing urinary tract infections in HIV patients